Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:BGMS NASDAQ:ONCO NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.98-8.9%$0.90$0.65▼$4.47$6.79M0.3339,626 shs537,682 shsBGMSCyclacel Pharmaceuticals$1.09+1.8%$1.01$0.73▼$26.10$5.91M-0.431,352 shs15,577 shsONCOOnconetix$1.14-0.4%$9.84$0.91▼$382.50$1.37M3.011.36 million shs406,144 shsRDHLRedhill Biopharma$1.02+1.6%$0.91$0.71▼$3.31$5.19M4.98103,185 shs24,890 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+3.88%+25.88%+21.58%+34.96%+18.76%BGMSCyclacel Pharmaceuticals-2.73%+10.31%+9.18%+11.46%+106,999,900.00%ONCOOnconetix-5.00%-8.06%-82.05%-96.84%-99.64%RDHLRedhill Biopharma0.00%+2.05%-7.83%+5.26%-44.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.98-8.9%$0.90$0.65▼$4.47$6.79M0.3339,626 shs537,682 shsBGMSCyclacel Pharmaceuticals$1.09+1.8%$1.01$0.73▼$26.10$5.91M-0.431,352 shs15,577 shsONCOOnconetix$1.14-0.4%$9.84$0.91▼$382.50$1.37M3.011.36 million shs406,144 shsRDHLRedhill Biopharma$1.02+1.6%$0.91$0.71▼$3.31$5.19M4.98103,185 shs24,890 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+3.88%+25.88%+21.58%+34.96%+18.76%BGMSCyclacel Pharmaceuticals-2.73%+10.31%+9.18%+11.46%+106,999,900.00%ONCOOnconetix-5.00%-8.06%-82.05%-96.84%-99.64%RDHLRedhill Biopharma0.00%+2.05%-7.83%+5.26%-44.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 1.00SellN/AN/ABGMSCyclacel Pharmaceuticals 1.00SellN/AN/AONCOOnconetix 1.00SellN/AN/ARDHLRedhill Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ONCO, BGMS, APM, and RDHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/20/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/6/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/6/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026BGMSCyclacel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum GroupN/AN/AN/AN/A$2.17 per shareN/ABGMSCyclacel Pharmaceuticals$1.53M3.94N/AN/A$1.40 per share0.78ONCOOnconetix$735.20K1.76N/AN/A$505.29 per share0.00RDHLRedhill Biopharma$290K18.18N/AN/A$0.83 per share1.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$1.36MN/AN/AN/AN/AN/AN/AN/AN/ABGMSCyclacel Pharmaceuticals-$3M-$4.54N/AN/AN/AN/A-51.21%-44.00%N/AONCOOnconetix-$14.03M$11.400.10N/AN/A-1,316.28%-101.08%-47.34%8/17/2026 (Estimated)RDHLRedhill Biopharma-$430K$1,046.750.00N/AN/AN/AN/AN/A8/20/2026 (Estimated)Latest ONCO, BGMS, APM, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BGMSCyclacel PharmaceuticalsN/A-$0.04N/A-$0.04N/AN/A5/13/2026Q1 2026ONCOOnconetixN/A-$67.10N/A-$6.71N/A$0.02 million3/30/2026Q4 2025BGMSCyclacel PharmaceuticalsN/A-$2.21N/A-$2.21N/A$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ABGMSCyclacel PharmaceuticalsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.780.78BGMSCyclacel PharmaceuticalsN/A7.065.87ONCOOnconetixN/A1.411.37RDHLRedhill BiopharmaN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%BGMSCyclacel Pharmaceuticals23.58%ONCOOnconetix23.89%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%BGMSCyclacel Pharmaceuticals23.75%ONCOOnconetix0.27%RDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group306.35 million2.29 millionNot OptionableBGMSCyclacel Pharmaceuticals145.52 million4.21 millionN/AONCOOnconetix121.14 million1.14 millionN/ARDHLRedhill Biopharma2105.19 million4.84 millionNo DataONCO, BGMS, APM, and RDHL HeadlinesRecent News About These CompaniesRedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense PlatformsJune 2 at 8:00 AM | prnewswire.comBessor Announces Entering Option for the Redhill PropertyMay 26, 2026 | globenewswire.comRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseApril 30, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical ...April 23, 2026 | finanznachrichten.deRedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026April 22, 2026 | prnewswire.comJoint U.S. Commercialization of RedHill's Talicia® CommencesFebruary 25, 2026 | prnewswire.comRedhill Biopharma stock soars on GLP-1 side effect treatment progressJanuary 5, 2026 | investing.comRedHill Biopharma shares jump on progress toward treating GLP-1 side effectsJanuary 5, 2026 | msn.comRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsJanuary 5, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | finanznachrichten.deRedHill Biopharma announces in vivo results on opaganib, venetoclaxDecember 15, 2025 | msn.comRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | prnewswire.comRedHill Biopharma regains compliance with Nasdaq equity requirementDecember 1, 2025 | msn.comRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity RequirementDecember 1, 2025 | prnewswire.comRedHill Biopharma announces $10.5M New York Supreme Court judgment winNovember 4, 2025 | msn.comRedhill Biopharma stock jumps after court win against KukboNovember 4, 2025 | za.investing.comRedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for EnforcementNovember 4, 2025 | prnewswire.comRedHill Biopharma Appeals Nasdaq Delisting Notice After Equity BoostOctober 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCO, BGMS, APM, and RDHL Company DescriptionsAptorum Group NASDAQ:APM$0.98 -0.10 (-8.88%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Cyclacel Pharmaceuticals NASDAQ:BGMS$1.09 +0.02 (+1.78%) As of 03:17 PM Eastern This is a fair market value price provided by Massive. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.Onconetix NASDAQ:ONCO$1.14 -0.01 (-0.44%) As of 03:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Redhill Biopharma NASDAQ:RDHL$1.02 +0.02 (+1.60%) As of 03:15 PM Eastern This is a fair market value price provided by Massive. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
